Discontinuation from randomised treatment is a common intercurrent event in clinical trials. When the target estimand uses a treatment policy strategy to deal with this intercurrent event, data after cessation of treatment is relevant to estimate the estimand and all efforts should be made to collect such data. Missing data may nevertheless occur due to participants withdrawing from the study and assumptions regarding the values for data that are missing are required for estimation. A missing-at-random assumption is commonly made in this setting, but it may not always be viewed as appropriate. Another potential approach is to assume missing values are similar to data collected after treatment discontinuation. This idea has been previously proposed in the context of recurrent event data. Here we extend this approach to time-to-event outcomes using the hazard function. We propose imputation models that allow for different hazard rates before and after treatment discontinuation and use the posttreatment discontinuation hazard to impute events for participants with missing follow-up periods due to study withdrawal. The imputation models are fitted as Andersen-Gill models. We illustrate the proposed methods with an example of a clinical trial in patients with chronic obstructive pulmonary disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pst.2189 | DOI Listing |
Aesthetic Plast Surg
January 2025
Department of Plastic and Reconstructive Surgery, Rambam Health Care Campus, 8thHa'Aliya Hashniya st, Haifa, Israel.
Background: Medical tourism is a rapidly expanding multi-billion-dollar industry. Reduced costs, all-inclusive vacation packages that include cosmetic surgery, globalization, and affordable flight expenses have encouraged patients to seek aesthetic procedures in different countries. Cosmetic medical tourism is associated with high complication rates, such as severe infections, wound dehiscence, pain or discomfort, aesthetic dissatisfaction, and even death.
View Article and Find Full Text PDFThe ejaculatory reflex consists of emission and expulsion, with the latter involving rhythmic muscular contractions that propel seminal fluid. Botulinum toxin, through its inhibitory effects, has been hypothesized to improve premature ejaculation (PE). This study evaluates high-quality evidence on botulinum toxin-A injections into the bulbospongiosal muscle as a treatment for PE.
View Article and Find Full Text PDFEur J Hum Genet
January 2025
CENTOGENE GmbH, Rostock, Germany.
We aimed to assess the impact of splicing variants reported in our laboratory to gain insight into their clinical relevance. A total of 108 consecutive individuals, for whom 113 splicing variants had been reported, were selected for RNA-sequencing (RNA-seq), considering the gene expression in blood. A protocol was developed to perform RNA extraction and sequencing using the same sample (dried blood spots, DBS) provided for the DNA analysis, including library preparation and bioinformatic pipeline analysis.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Medical Oncology, Sasebo Kyosai Hospital, Sasebo, Japan.
The relationship between nanoliposomal irinotecan/fluorouracil/leucovorin (NFF) treatment outcomes and neutropenia in patients with pancreatic cancer has not been thoroughly examined. Thus, we conducted a retrospective analysis of data from patients with pancreatic cancer who were treated with NFF to investigate this relationship. Neutropenia was assessed according to the Common Terminology Criteria for Adverse Events across three cutoffs: A (grade 0 versus grade 1-4), B (grades 0-1 versus 2-4), and C (grades 0-2 versus 3-4).
View Article and Find Full Text PDFSci Rep
January 2025
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon, 16247, Korea.
Advanced hepatocellular carcinoma (HCC) poses treatment challenges, especially where access to multi-kinase inhibitors and ICIs is limited by high costs and lack of insurance. This study evaluates the effectiveness of 5-fluorouracil (5-FU) plus platinum-based chemotherapy as an alternative systemic treatment for advanced HCC. A retrospective analysis of advanced HCC patients treated with 5-FU plus platinum-based chemotherapy was conducted.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!